Given the critical importance of advanced bioanalytics and product characterisation for developing increasingly complex therapeutics, Ampersand has invested nearly $40m within the past year to support ProtaGene's services and capacity expansions.
This investment has allowed the organisation to meet rebounding market demand among biologics developers, address increasingly complex analytical challenges and deliver the growing product understanding and safety assurances required by global regulatory bodies.
Investments fuelled capacity and capabilities expansions
Ampersand's investments have been pivotal in ProtaGene's worldwide expansion efforts, including establishing cutting-edge facilities in North America and Europe.
Most recently, ProtaGene unveiled a brand-new, state-of-the-art lab and office headquarters in the Burlington BioCenter, located in Boston's rapidly growing biotechnology hub.
This capital has also been instrumental in enabling ProtaGene to enhance its global offerings, encompassing integration site analysis (ISA), a comprehensive suite of bioanalytical services (including biodistribution, vector shedding and transgene expression analysis), Chemistry, Manufacturing and Controls (CMC) solutions and specialised support for biosimilars.
These advancements effectively address the ever-evolving needs of clients across the globe.
Funds allocated for industry leading equipment and services
The investment will enable ProtaGene to procure state-of-the-art equipment and technology for characterising novel biologics and gene therapies.
This intention underscores ProtaGene's mission to provide world-class solutions supporting the dynamic biopharmaceutical and cell and gene therapy sector.
Ampersand's continued investment in ProtaGene reflects its commitment to progressing innovation and excellence in advanced analytics, essential capabilities needed to enable the discovery and development of novel therapeutics addressing vexing disease states for patients worldwide.
